TASK Applied Science
🇿🇦South Africa
- Country
- 🇿🇦South Africa
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.task.org.za/
Clinical Trials
7
Active:0
Completed:6
Trial Phases
2 Phases
Phase 2:6
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
6 (85.7%)Phase 3
1 (14.3%)A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination with Ethionamide
Phase 2
Recruiting
- Conditions
- Tuberculosis
- Interventions
- Drug: Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg ODDrug: Alpibectir 45 mg OD plus Ethionamide 250 mg ODDrug: Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight basedDrug: Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 60
- Registration Number
- NCT06748937
- Locations
- 🇿🇦
TASK, Cape Town, Western Cape, South Africa
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
Phase 2
Completed
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Drug: Rifafour e-275Drug: Amoxicillin/CA twice dailyDrug: Amoxicillin/CA once daily
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 134
- Registration Number
- NCT05896930
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098
Phase 2
Completed
- Conditions
- Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 105
- Registration Number
- NCT05473195
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
EBA, Safety and Tolerability of Sanfetrinem Cilexetil
Phase 2
Completed
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 54
- Registration Number
- NCT05388448
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
Phase 2
Completed
- Conditions
- Tuberculosis
- Interventions
- Drug: RifafourDrug: Amoxicillin Clavulanate
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 22
- Registration Number
- NCT04629378
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
- Prev
- 1
- 2
- Next
News
No news found